SciCheck Digest
A uncommon threat of harmful blood clots related to the AstraZeneca COVID-19 vaccine was recognized and reported in early 2021. This month, the corporate introduced it was pulling the vaccine off the market globally, citing a decline in demand. Social media posts misleadingly linked the choice to the corporate having “admitted” the uncommon facet impact “for the primary time” in courtroom paperwork and used it to impugn all vaccines.
Full Story
The affiliation between the AstraZeneca COVID-19 vaccine and a uncommon and harmful blood clotting situation mixed with low blood platelets has been identified for greater than three years. The situation is called thrombosis with thrombocytopenia syndrome, or TTS, normally, and vaccine-induced thrombotic thrombocytopenia, or VITT, when it implies an affiliation to vaccines.
The European Medicines Company, which regulates vaccines within the European Union, first warned of the attainable hyperlink between the vaccine and “very uncommon instances of blood clots related to thrombocytopenia, i.e. low ranges of blood platelets” on March 18, 2021. In a statement issued that very same day, the pharmaceutical firm acknowledged the discovering and mentioned it “recognises and can implement” EMA’s suggestions, together with updating the product info to warn concerning the reported instances.
A couple of weeks later, in April 2021, the EMA concluded the bizarre blood clots “needs to be listed as very uncommon uncomfortable side effects” of the vaccine. TTS is included within the “attainable uncomfortable side effects” part within the package leaflet for customers for Vaxzevria (web page 30), one of many model names of the vaccine together with Covishield. TTS has additionally been listed in Covishield’s product insert below the “particular warnings” part, as a facet impact within the fact sheet for recipients since no less than August 2021, and as a attainable adversarial response in an FAQ page from its producer that was up to date on July 5, 2021.
In September 2021, the Nationwide Well being Service in England reported that the “uncommon situation” affected roughly 1 in 50,000 AstraZeneca COVID-19 vaccine recipients below 50 years outdated and 1 in 100,000 recipients older than 50. Between Could 2021 and Could 2022, there have been 443 cases of TTS reported following vaccination within the U.Ok.; 81 of them had been deadly. (In July 2021, the vaccine was additionally linked to uncommon instances of Guillain-Barré syndrome, a neurological dysfunction that results in muscle weak spot and, at occasions, paralysis. The World Well being Group mentioned that most individuals get better totally.)
The vaccine was by no means used within the U.S. exterior scientific trials — AstraZeneca decided to not file the applying for approval. However the vaccine was broadly utilized in the remainder of the world, particularly throughout 2021.
In March, the European Fee withdrew AstraZeneca’s authorization to market its COVID-19 vaccine within the European Union, on the firm’s request, and on Could 7, the company announced it was pulling the vaccine from the market globally. Social media posts misleadingly framed the corporate’s latest resolution as a consequence of “admitting” the uncommon TTS situation “for the primary time” in courtroom paperwork, as a part of a lawsuit within the U.Ok. The declare was additionally shared in Spanish.
AstraZeneca had said the choice was based mostly on a decline in demand. Different COVID-19 vaccine producers had developed new variations to focus on variants of the virus that causes COVID-19. “As a number of, variant COVID-19 vaccines have since been developed there’s a surplus of obtainable up to date vaccines,” the corporate mentioned in a press release despatched to us.
“AstraZeneca lastly WITHDRAW Covid vaccine worldwide, months after the pharmaceutical big admitted for the primary time in courtroom paperwork that it may trigger ‘a uncommon and harmful’ facet impact. Always remember how they cancelled anybody who questioned its security,” reads a viral post shared throughout social media platforms.
The U.Ok. information web site the Telegraph had reported on April 28 that AstraZeneca had “admitted” its COVID-19 vaccine might trigger TTS “in an obvious about-turn that might pave the way in which for a multi-million pound authorized payout” in a category motion lawsuit through which the corporate is being sued for “loss of life and critical damage in dozens of instances.” The article mentioned the corporate hadn’t mentioned that in a courtroom doc earlier than. However the story went on to say {that a} hyperlink between the vaccine and the uncommon blood clotting situation was recognized in March 2021, as we mentioned.
On Could 7, the Telegraph reported that AstraZeneca was “being withdrawn worldwide, months after the pharmaceutical big admitted for the primary time in courtroom paperwork that it may trigger a uncommon and harmful facet impact.” The following day, the Unbiased, a British on-line newspaper, printed a story with the headline “AstraZeneca withdraws Covid vaccine worldwide after admitting it may trigger uncommon blood clots.”
Christina Pagel, professor of operational analysis at College Faculty London, mentioned the headlines had been “needlessly scary” on her blog on Could 8, and days later in an op-ed with Sheena Cruickshank, immunologist on the College of Manchester, within the New Statesman, a U.Ok. publication.
“Basically, the state of affairs is that this: there isn’t a brand new ‘smoking gun’; the AZ vaccine was one of many first and most cost-effective vaccines; it saved hundreds of thousands of lives globally; and there are higher vaccines on the market now, tailored to new variants,” they wrote.
AstraZeneca’s COVID-19 Vaccine Security and Impression
Regardless that the uncommon threat related to the AstraZeneca COVID-19 vaccine was reported early on and was well-known, some social media customers took the Telegraph’s information reviews as vindication.
“Now they admit it,” wrote conservative commentator Dan Bongino in a Fb publish, linking to a Rumble video titled “AstraZeneca Makes SHOCKING Admission About COVID Vax – We Have been Proper All Alongside.”
Others used the obvious information to forged shade on all different COVID-19 vaccines. “It’s not simply the Astra Zeneca,” one Fb post mentioned.
A commenter to a publish on Instagram wrote, “Whens the category motion lawsuit towards the US Authorities?,” though the vaccine was not approved to be used within the U.S. One other one wrote, “When will Pfizer lastly step up and do the identical?,” though the Pfizer/BioNTech COVID-19 vaccine has not been linked to TTS.
Identical to different COVID-19 vaccines approved or accredited to be used, the AstraZeneca COVID-19 vaccine, co-developed by Oxford College, was found to be protected and efficient for individuals over 18 years outdated in scientific trials and in additional research. The efficacy of the vaccine in stopping symptomatic illness in scientific trials was 74%, which was decrease than its mRNA counterparts, particularly the Pfizer/BioNTech and Moderna vaccines.
After the possibly lethal blood clot facet impact was recognized in 2021, many international locations restricted the AstraZeneca vaccine use for under older populations. The reported TTS instances had been extra prevalent amongst these youthful than 50.
As a result of AstraZeneca’s vaccine was cheaper and easier to distribute than different COVID-19 vaccines, it was among the many first vaccines despatched to poorer international locations by COVAX, a world initiative that allowed for equitable entry to COVID-19 vaccines.
Since its rollout, greater than 3 billion doses had been distributed in over 180 international locations, according to a 2022 assertion from the vaccine builders, with roughly two-thirds of the doses going to poorer international locations. A 2022 analysis by Airfinity, a disease-forecasting firm, confirmed that the vaccine saved 6.3 million lives from December 2020 to December 2021. The corporate used information from a study by scientists with the Imperial Faculty London on the worldwide affect of COVID-19 vaccination throughout that 12 months.
Vaccines within the U.S.
As we mentioned, the AstraZeneca COVID-19 vaccine was not used within the U.S. exterior scientific trials.
The Johnson & Johnson COVID-19 vaccine, although, makes use of the identical platform because the AstraZeneca vaccine. Each use a modified, innocent adenovirus, a kind of virus that sometimes causes the widespread chilly, to set off an immune response. The J&J vaccine was granted an emergency use authorization in February 2021, however quickly after, in April of that 12 months, the Meals and Drug Administration and the Facilities for Illness Management and Prevention reported cases of TTS following the administration of the vaccine and really useful a “pause” in its use. The FDA additionally reported rare cases of GBS in July 2021.
The FDA limited the authorization of the J&J vaccine to sure individuals in Could 2022, and the vaccine was finally discontinued in 2023. As of April 7, 2022, the CDC and FDA had confirmed 60 instances of TTS, together with 9 deaths, amongst greater than 18.6 million J&J vaccines administered. In September 2023, the CDC said TTS after J&J COVID-19 vaccination “has occurred in roughly 4 instances per a million doses administered.”
The primary two COVID-19 vaccines approved and accredited within the U.S., the Pfizer/BioNTech and Moderna vaccines, are each mRNA vaccines. The mRNA COVID-19 vaccines had been broadly used within the U.S., and neither has been linked to TTS. For context, as of April 26, 2023, roughly 367 million doses of the Pfizer/BioNTech vaccine, 232 million doses of the Moderna vaccine and 19 million doses of the J&J vaccine had been administered within the nation.
Each mRNA vaccines have been proven to be protected, with rare serious side effects reported, and efficient at stopping extreme COVID-19 illness and loss of life. One estimate printed in December 2022 suggests that COVID-19 vaccines prevented greater than 18 million hospitalizations and three million deaths within the U.S.
Editor’s observe: SciCheck’s articles offering correct well being info and correcting well being misinformation are made attainable by a grant from the Robert Wooden Johnson Basis. The muse has no control over FactCheck.org’s editorial selections, and the views expressed in our articles don’t essentially mirror the views of the inspiration.
Sources
“COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets.” Press launch. European Medicines Company. 18 Mar 2021.
“UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is effective and generally well-tolerated.” Assertion. AstraZeneca. Up to date 9 Mar 2022.
“AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets.” Press launch. European Medicines Company. 7 Apr 2021.
“Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines.” Assertion. WHO. 26 Jul 2021.
Kiely, Eugene and Catalina Jaramillo. “The Facts on the Recommended J&J Vaccine ‘Pause’.” FactCheck.org. Up to date 6 Could 2022.
“Coronavirus (COVID-19) Update: July 13, 2021.” Press launch. FDA. 13 Jul 2021.
Robertson, Lori. “A Guide to Johnson & Johnson’s COVID-19 Vaccine.” FactCheck.org. Up to date 19 Apr 2024.
“AstraZeneca pulls its COVID-19 vaccine from the European market.” AP. 8 Could 2024.
Robbins, Rebecca. “AstraZeneca Is Withdrawing Its Covid Vaccine Worldwide, Citing Low Demand.” New York Occasions. 8 Could 2024.
Davey, Melissa. “AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines.” The Guardian. 7 Could 2024.
AstraZeneca international media group. Electronic mail to FactCheck.org. 16 Could 2024.
Investigations group and Robert Mendick. “AstraZeneca admits its Covid vaccine can cause rare side effect in court documents for first time.” The Telegraph. 28 Apr 2024.
Mendick, Robert, and Patrick Sawer. “AstraZeneca withdrawing Covid vaccine worldwide.” The Telegraph. 7 Could 2024.
Rai, Arpan. “AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots.” The Indipendent. 8 Could 2024.
Pagel, Christina. “The Astra Zeneca Covid vaccine saved millions of lives globally.” Diving into Information & Determination making. 8 Could 2024.
Pagel, Christina and Sheena Cruickshank. “The AstraZeneca vaccine saved millions of lives – it should not be demonised.” The New Stateman. 16 Could 2024.
“The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what you need to know.” WHO. Up to date 13 Jun 2022.
Ramasamy, Maheshi N., et al. “Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.” The Lancet. Quantity 396, Subject 10267, 19 Dec 2020.
“Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults.” ClinicalTrials.gov. 5 Feb 2024.
Falsey, Ann R., et al. “Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.” The New England Journal of Drugs. 29 Sep 2021.
“Vaccine-induced Immune Thrombotic Thrombocytopenia.” American Society Hematology. 9 Could 2022.
“Some countries limit AstraZeneca vaccine use, U.S. pauses J&J shot.” Reuters. 25 Mar 2021.
“Vaccine-induced thrombocytopenia and thrombosis (VITT) Support for patients family members.” NHS England. 14 Sep 2021.
Hippisley-Cox, Julia, et al. “Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.” BMJ. 27 Aug 2021.
“AstraZeneca no longer pursuing U.S. approval for COVID vaccine.” Reuters. 10 Nov 2022.
Mallapaty, Smriti and Ewen Callaway. “What scientists do and don’t know about the Oxford–AstraZeneca COVID vaccine.” Nature. 25 Mar 2021.
Callaway, Ewen and Smriti Mallapaty. “Latest results put Oxford–AstraZeneca COVID vaccine back on track.” Nature. 25 Mar 2021.
“First COVID-19 COVAX vaccine doses administered in Africa.” Press launch. WHO. 1 Mar 2021.
“Boosting with AstraZeneca’s vaccine provides high protection against Omicron, equivalent to mRNA COVID-19 vaccines.” Press launch. AstraZeneca. 8 Sep 2022.
“Oxford vaccine saved most lives in its first year of rollout.” College of Oxford. 15 Jul 2022.
“AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination.” Press launch. Airfinity. 12 Jul 2022.
Lane, Samantha, and Saad Shakir. “Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.” Drug Security. 4 Aug 2022.
Watson, Oliver J., et al. “Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.” The Lancet. 23 June 2022.
“Selected Adverse Events Reported after COVID-19 Vaccination.” CDC. 12 Sep 2023.
Fitzpatrick, Meagan C., et al. “Two Years of U.S. COVID-19 Vaccines Have Prevented Millions of Hospitalizations and Deaths.” The Commonwealth Fund. 13 Dec 2022.
“Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR – Product information.” EMA. 7 Apr 2024.
“ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) COVISHIELD™“. Serum Institute of India web site. Accessed 22 Could 2024.
